Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma

被引：17

作者：

Sun, Danyang ^{[1
,2
]}

Zheng, Xiangqian ^{[3
]}

He, Xianghui ^{[4
]}

Huang, Chao ^{[5
]}

Jia, Qiang ^{[2
]}

Tan, Jian ^{[2
]}

Zheng, Wei ^{[2
]}

Li, Ning ^{[2
]}

Wang, Peng ^{[2
]}

Wang, Renfei ^{[2
]}

Liu, Ming ^{[6
]}

Zhao, Li ^{[7
]}

Yuan, Shukai ^{[7
]}

Meng, Zhaowei ^{[1
,2
]}

Fan, Yaguang ^{[8
]}

机构：

[1] Tianjin Med Univ Gen Hosp Airport Site, Dept Nucl Med, Tianjin, Peoples R China

[2] Tianjin Med Univ Gen Hosp, Dept Nucl Med, Tianjin, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Thyroid & Neck Tumor, Key Lab Canc Prevent & Therapy Tianjin City, Tianjin, Peoples R China

[4] Tianjin Med Univ Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China

[5] Univ Hull, Hull York Med Sch, Stat, Kingston Upon Hull, N Humberside, England

[6] Tianjin Med Univ Gen Hosp, Dept Endocrinol & Metab, Tianjin, Peoples R China

[7] Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin, Peoples R China

[8] Tianjin Med Univ Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China

来源：

BIOMARKERS IN MEDICINE | 2020年 / 14卷 / 18期

基金：

中国国家自然科学基金;

关键词：

I-131; therapy; antithyroglobulin antibody; differentiated thyroid cancer; half-life; thyroglobulin; SERUM THYROGLOBULIN ANTIBODY; MANAGEMENT GUIDELINES; CLINICAL-SIGNIFICANCE; NEGATIVE PATIENTS; CANCER; DISEASE; I-131; RECURRENCE; ABLATION; TGAB;

D O I：

10.2217/bmm-2019-0432

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Background: The clinical value of antithyroglobulin antibodies (TgAb) as a tumor marker for differentiated thyroid cancer (DTC) is still controversial. Materials & methods: We studied 110 TgAb positive DTC patients who underwent total thyroidectomy and I-131 therapies. Multivariate logistic regression was conducted to analyze the association between prognostic factors and disease outcomes. Results & conclusion: Pre-ablation TgAb levels and the changes of TgAb in 6-12 months after the first I-131 therapy were risk factors for disease outcome in patients younger than 55, while extrathyroid extension was a risk factor in patients older than 55. The median TgAb half-life was 7.7 months and the median time for TgAb positivity to become negative was 15.8 months. The dynamics of TgAb within the first year after remnant ablation could predict disease outcome for DTC patients.

引用

页码：1683 / 1692

页数：10

共 38 条

[1]

Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens [J].